20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
MENLO PARK, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment options, announced today that Amber Salzman, Ph.D., president and chief executive officer of Adverum, will present at two upcoming investor conferences:
- Cowen and Company 37th Annual Health Care Conference
Date: Monday, March 6, 2017
Time: 2:40pm ET
Location: Boston, MA - 29th Annual ROTH Conference
Date: Monday, March 13, 2017
Time: 7:30am PT
Location: Laguna Niguel, CA
The audio portions of the corporate presentations will be accessible live through the investors' section of the Company's website at www.adverum.com. A replay will be available for 14 days following the presentations.
About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or diseases of the eye who currently have limited or burdensome treatment options. Adverum has a robust pipeline that includes product candidates to treat wet age-related macular degeneration (wAMD), alpha-1 antitrypsin (A1AT) deficiency, and hereditary angioedema (HAE). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum has clinical development expertise and core capabilities in vector optimization, process development, manufacturing, and assay development. For more information please visit www.adverum.com.
Contact for Adverum: Leone PattersonChief Financial OfficerAdverum Biotechnologies, Inc.650-665-7222lpatterson@adverum.comJill SteierSenior Vice PresidentThe Trout Group LLC646-378-2946jsteier@troutgroup.com
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!